title: Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3.
abstract: The objective of this study was to determine health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) as measured by the "routine assessment of patient index data 3" (RAPID3) and whether RAPID3 is correlated with disease activity as determined by the Birmingham Vasculitis Activity Score (BVAS). Data from patients at an academic institution vasculitis clinic seen between Jan 2010 and Jan 2012 were collected using chart review. BVAS and RAPID3 scores were calculated at each patient visit. RAPID3 was compared between patients in remission (BVAS = 0) and patients with active disease (BVAS > =1) at all visits for four consecutive visits, when data available, at least 3 months apart during the period mentioned. Robust generalized estimating equations (GEE) in linear regression models evaluated associations between the RAPID3 and BVAS over all available observations, adjusting for intra-subject correlations. Thirty-four patients were included in the study, 26 had granulomatosis with polyangiitis (GPA), five microscopic polyangiitis (MPA), and three eosinophilic granulomatosis with polyangiitis (EGPA). Patients at first visit had impaired HRQoL as measured by RAPID3 [6.8 (3.1-12.6)]. The median RAPID3 scores were higher in patients with active disease as compared to patients in remission (7.0 vs. 3.0, p = 0.115; 8.8 vs. 1.0, p = 0.011; 6.1 vs. 2.0, p = 0.032; and 11.7 vs. 2.0, p = 0.128 for visits 1, 2, 3, and 4, respectively). In longitudinal GEE models incorporating all observations there was a strong association between the RAPID3 (per 1 unit) and BVAS (per 1 unit) [β 0.21 (0.10, 0.32) p < 0.001]. RAPID3 can be used to measure HRQoL in patients with AAV. RAPID3 correlated significantly with BVAS. RAPID3 can discriminate between disease states in AAV. This instrument may help document patient experience and add to clinical decisions.
authors.affiliation: Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA.|Division of Rheumatology, Rush University, Chicago, IL, USA.
authors.forename: Narender
authors.initials: N
authors.lastname: Annapureddy
authors.affiliation: Department of Medicine, Creighton University, Omaha, NE, USA.
authors.forename: Osama
authors.initials: O
authors.lastname: Elsallabi
authors.affiliation: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA.|Division of Rheumatology, University of Pennsylvania, 3400 Spruce Street, 1407 Penn tower, Philadelphia, PA, 19104, USA.|Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Joshua
authors.initials: J
authors.lastname: Baker
authors.affiliation: Division of Rheumatology, University of Pennsylvania, 3400 Spruce Street, 1407 Penn tower, Philadelphia, PA, 19104, USA. antoine.sreih@uphs.upenn.edu.|Division of Rheumatology, Rush University, Chicago, IL, USA. antoine.sreih@uphs.upenn.edu.
authors.forename: Antoine G
authors.initials: AG
authors.lastname: Sreih
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
keywords: ANCA-associated Vasculitis; Disease activity measures; Patient-Reported Outcomes; RAPID3; Validation of measures
references.citation: Bull NYU Hosp Jt Dis. 2011;69(3):201-14
references.pmid: 22035430
references.citation: Arthritis Rheum. 2003 Dec 15;49(6):826-37
references.pmid: 14673970
references.citation: QJM. 1994 Nov;87(11):671-8
references.pmid: 7820541
references.citation: Arthritis Care Res (Hoboken). 2012 Feb;64(2):273-9
references.pmid: 21954229
references.citation: J Rheumatol. 2011 Jul;38(7):1309-16
references.pmid: 21459938
references.citation: Arthritis Rheum. 1994 Feb;37(2):187-92
references.pmid: 8129773
references.citation: Rheumatology (Oxford). 2013 Oct;52(10):1856-64
references.pmid: 23843108
references.citation: Bull NYU Hosp Jt Dis. 2010;68(2):130-9
references.pmid: 20632989
references.citation: Arthritis Rheum. 1999 Oct;42(10):2220-30
references.pmid: 10524697
references.citation: Bull NYU Hosp Jt Dis. 2008;66(2):155-65
references.pmid: 18537789
references.citation: Arthritis Rheum. 1998 Dec;41(12):2257-62
references.pmid: 9870883
references.citation: Rheum Dis Clin North Am. 2009 Nov;35(4):819-27, x
references.pmid: 19962626
references.citation: J Rheumatol. 2009 Oct;36(10):2362-8
references.pmid: 19820226
references.citation: Diabetes Educ. 2008 Sep-Oct;34(5):815-23
references.pmid: 18832286
references.citation: Arthritis Rheum. 1990 Aug;33(8):1135-6
references.pmid: 2202312
references.citation: Cleve Clin J Med. 2012 Nov;79 Suppl 3:S11-5
references.pmid: 23203638
references.citation: Rheumatology (Oxford). 2011 May;50(5):899-905
references.pmid: 21156667
references.citation: Arthritis Care Res (Hoboken). 2013 Nov;65(11):1835-43
references.pmid: 23861259